Alliance A021602: Randomized, Double-Blinded Phase III Study of Cabozantinib vs. Placebo in Patients with Advanced Neuroendocrine Tumors After Progression on Everolimus (CABINET)

Summary

This randomized phase III trial studies cabozantinib S-malate to see how well it works compared with placebo in treating patients with neuroendocrine tumors previously treated with everolimus that have spread to nearby tissues or lymph nodes, have spread to other places in the body, or cannot be removed by surgery. Cabozantinib S-malate is a chemotherapy drug known as a tyrosine kinase inhibitor, and it targets specific tyrosine kinase receptors, that when blocked, may slow tumor growth.

More information

Contact us

To learn more about clinical trials at ProHealth Care, email research.institute@phci.org or call 262-928-3447.

Quick Access Links